Retatrutide

Retatrutide, commonly shortened to Reta, is available in batch-specific research quantities from 10mg to 60mg. It is a triple-hormone receptor agonist peptide that simultaneously activates GLP-1, GIP, and glucagon (GCG) receptors. This multi-target mechanism has made it a compound of significant interest in metabolic research, particularly in studies exploring energy homeostasis, multi-receptor signalling, and metabolic flexibility.

Areas of Interest

Laboratory studies of Retatrutide have investigated a variety of promising areas:

• •Energy homeostasis & metabolic flexibility — studied for its effects on energy expenditure, substrate utilisation, and metabolic adaptation in preclinical models.
• •Receptor crosstalk & downstream signalling — investigated for coordinated intracellular signalling through GLP-1, GIP, and glucagon receptors in metabolic research models.
• •Triple agonist receptor pharmacology — explored as a tool for understanding coordinated GLP-1, GIP, and glucagon receptor activation and their combined metabolic effects.
• •Insulin sensitivity & glucose metabolism — examined in cellular and in vitro models for effects on glucose uptake, insulin signalling, and glycaemic control.
• •Lipid metabolism & energy expenditure — studied for its potential effects on lipolysis, fatty acid oxidation, and overall energy balance in research settings.

As a research-grade reference material, our Retatrutide is supplied as a lyophilized powder with a purity of ≥99.1% as verified by HPLC and mass spectrometry. Each batch is accompanied by a Certificate of Analysis documenting sequence integrity, molecular weight confirmation, and chromatographic purity.